PT-141, known chemically as Bremelanotide, is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that functions as a non-selective melanocortin receptor agonist, with particular affinity for the MC4 receptor (MC4R) and secondary activity at MC3R. Unlike peripherally-acting compounds that target vascular smooth muscle, PT-141 is studied for its activity within the central nervous system, engaging melanocortin signaling pathways in the hypothalamus that are implicated in the regulation of sexual arousal and desire.

Preclinical and clinical research has examined PT-141’s activation of MC4R-expressing neurons in the paraventricular nucleus and its downstream influence on pathways associated with sexual response, independent of the nitric oxide/vascular pathway exploited by PDE5 inhibitor research. Studies have investigated its effects across both male and female models, with particular research interest in its CNS mechanism as a point of differentiation from vascular-based approaches. Research has also characterized its pharmacokinetic profile, receptor binding kinetics, and dose-dependent activation of downstream melanocortin signaling cascades.

This 10mg concentration supports research protocols requiring extended or higher-dose quantities for preclinical CNS pharmacology studies, melanocortin receptor binding assays, or in vitro mechanistic research.

PT-141 is a widely referenced compound in melanocortin receptor research and CNS-mediated sexual arousal pathway studies, valued for its distinct mechanism relative to vascular-targeting research compounds.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.